Stevens–Johnson syndrome and toxic epidermal necrolysis: 11-year demographic clinical and prognostic characteristics-Reference-Cited by-同舟云学术

Stevens–Johnson syndrome and toxic epidermal necrolysis: 11-year demographic clinical and prognostic characteristics

Published:2022 Issue:1 Volume:67 Page:12
ISSN:0019-5154
Container-title:Indian Journal of Dermatology
language:en
Short-container-title:Indian J Dermatol

Author:

Acar Ayda,Yoldas AyseH,Turk BenguG,Karaarslan Isil,Sagduyu IlgenE,Ceylan Can,Unal Idil,Ozturk Gunseli

Publisher

Medknow

Subject

Dermatology

Reference25 articles.

1. Hötzenecker W, Prins C, French LE. Erythema multiforme, Steven-Johnson syndrome, and toxic epidermal necrolysis. In: Bolognia JL, Schaffer JV, Cerroni L, editors. Dermatology. 4th ed. China; Elsevier; 2018. p. 332-47.

2. Stevens-Johnson syndrome and toxic epidermal necrolysis: An update;Dodiuk-Gad;Am J Clin Dermatol,2015

3. Creamer D, Walsh SA, Dziewulski P, Exton LS, Lee HY, Dart JK, et al. U.K. guidelines for the management of Stevens-Johnson syndrome/toxic Epidermal necrolysis in adults 2016. Br J Dermatol 2016;174:1194-227.

4. Guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis: An Indian perspective;Gupta;Indian J Dermatol Venereol Leprol,2016

5. SCORTEN: A severity-of-illness score for toxic epidermal necrolysis;Bastuji-Garin;J Invest Dermatol,2000

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Analysis of the Russian Database of Spontaneous Reports;Pharmaceuticals;2024-05-24

2. Assessment of Need for Improved Identification of a Culprit Drug in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis;JAMA Dermatology;2023-08-01

3. Pembrolizumab-induced toxic epidermal necrolysis: A rare cause of severe adverse drug reaction;Indian Journal of Dermatology, Venereology and Leprology;2023-01-25

4. RDW-SD and PCT Are Potential Prognostic Factors for In-hospital Death in Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis;Allergy, Asthma & Immunology Research;2023